Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study

Abstract

While the vaccination was introduced as a promising tool to control the Coronavirus disease 2019 (COVID-19) pandemic, concerns about vaccine-related side effects had grown. Due to the widespread administration of the COVID-19 vaccine worldwide for the first time, it was necessary to evaluate the safety and potential side effects in recipients. This study aims to assess, the incidence of adverse effects following Oxford-AstraZeneca vaccination and identify their related factors. In this cross-sectional survey-based study, 453 volunteers participated, including 235 men and 218 women. The reported adverse reactions from recipients of the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine were collected by using a questionnaire. The findings showed that the incidence of adverse reactions, such as neurological, systematic, gastrointestinal, respiratory, and local symptoms were significantly higher after the first dose compared to the second dose. Systematic symptoms were the most prevalent reported side effects after the first and second dose injection. The demographical study of participants showed that individuals aged 18–34 and females were more prone to present adverse events following vaccination. However, no significant relationship was found between the occurrence of side effects and the recipients’ body mass index. Despite the life-saving role of vaccination against SARS-CoV-2, it may have some adverse reactions in recipients. The severity and frequency of side effects were different. So, they were dependent on several factors, including gender and age. Altogether, post-vaccination adverse reactions were mild and tolerable.

Preliminary Report of Nationwide COVID-19 Vaccine Compensation in Taiwan

“…In this study, thrombosis events are predominantly associated with the AZ vaccine, consistent with previous research [8,9]. AEFI complaints were more common after the first dose of the AZ vaccine, aligning with existing literature [10]. Despite reports of higher AEFI rates after the second dose of mRNA vaccines [2], our study found more AEFI after the first dose of mRNA vaccines.…”

Preliminary Report of Nationwide COVID-19 Vaccine Compensation in Taiwan

“…In this study, thrombosis events were predominantly associated with the AZ vaccine, consistent with previous research [8,9]. AEFI complaints were more common after the first dose of the AZ vaccine, aligning with the existing literature [10]. Despite reports of higher AEFI rates after the second dose of mRNA vaccines [2], our study found more AEFI after the first dose of mRNA vaccines.…”

Distinct Adverse Reactions to mRNA, Inactivated Virus, and Adenovirus Vector COVID-19 Vaccines: Insights from a Cohort Study on Atopic and Non-Atopic Subjects in Brazil

“…In addition to conventional technologies, the COVID-19 pandemic catalyzed advancements in novel vaccine platforms [6]. The BNT162 mRNA vaccine, developed by Pfizer-BioNTech, and the ChAdOx1 adenoviral vector vaccine, developed by the University of Oxford-AstraZeneca, were the initial vaccines endorsed by the World Health Organization (WHO) for emergency deployment [7]. They have predominantly been adopted worldwide, complemented by the administration of other vaccines, such as the inactivated virus vaccine CoronaVac (Sinovac), which has primarily been distributed in low-and middle-income nations [8,9]; together, they markedly reduced the infection rates, severity, and mortality, preventing millions of deaths [10].…”